Since the first report of IFN-α as an effective treatment for CDA-I in 1995, [3] its use has been limited by the need for thrice-weekly or twice-weekly injections, which affects long-term adherence. Here, IFNA1 is linked to Congenital dyserythropoietic anemia type I.